Advisors Capital Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 31,697 shares of the biopharmaceutical company's stock, valued at approximately $4,005,000. Other institutional investors and hedge funds

Allworth Financial LP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 47,192 shares of the biopharmaceutical company's stock, valued at approximately $5,962,000. Several other hedge funds and other institutional

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

Abacus FCF Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 59,974 shares of the biopharmaceutical company's stock, valued at approximately $7,577,000. A number of other hedge

San Diego, California--(Newsfile Corp. - August 19, 2026) - Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton Holdings Ltd (NASDAQ: PTHL) (n/k/a iTonic Holdings Ltd. (NASDAQ: ITOC)) securities between September 5, 2024 and July 29, 2025 (the "Class Period").

These stocks can be safe-haven investments to hide out in amid market turmoil.

Aljian Capital Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 4,496 shares of the biopharmaceutical company's stock, valued at approximately $568,000. A number of other institutional investors and hedge funds have also recently

Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.

Capital Financial Group Inc. Co. ADV bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,605 shares of the biopharmaceutical company's stock, valued at approximately $582,000. A number of other large investors have